Clinical Trials Browser

Phase 4 × Withdrawn × pasireotide × Clear all

NCT02779257 2022-03-04

Pasireotide Treatment for Neuroendocrine Tumor

Phase 4 Withdrawn

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Hypoglycemia